$XBI $63.97 | -2.6%
Table of Contents:
Covid Updates
Pipeline Updates
#PSTV +3.5% PLUS THERAPEUTICS COMPLETES ENROLLMENT OF COHORT 1 RESPECT-LM PHASE 1/2A TRIAL
#EWTX +1.1% New 2-Month Interim Data From The ARCH Open Label Study Of EDG-5506 In Individuals With Becker Muscular Dystrophy (BMD) To Be Presented At The Upcoming New Directions In Biology And Disease Of Skeletal Muscle Conference
#LVTX -2.5% LAVA THERAPEUTICS HIGHLIGHTS ENCOURAGING CLINICAL UPDATES ON LEAD PROGRAM, LAVA-051, IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA PATIENTS
#EVFM -2.7% Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data
#CKPT -2.8% Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma
#CYTK -3.6% Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS
#MBRX -4.3% Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
#RYTM +13% (-10.8% Aftr mrkt) Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Use in Patients with Bardet-Biedl Syndrome
#RYTM +13% (-10.8% Aftr mrkt) Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million
#ACIU -17.8% AC Immune Provides Update On Alzheimer’s Prevention Initiative Study Evaluating Crenezumab In Autosomal Dominant Alzheimer’s Disease
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
#HGEN -5.7% Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
#PLRX -1.0% Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration
Posted by JM